Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad5-MuLV gp70
- Development stage
- Preclinical
- Lead developer
- University Hospital Erlangen
- Modality
- Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Intramuscular, Intranasal
01
Overview
Ad5-MuLV gp70 is a preclinical recombinant adenovirus serotype 5 (Ad5) viral vector vaccine encoding the envelope glycoprotein gp70 of the murine leukemia virus (MuLV). Developed by researchers at the University Hospital Erlangen, this vaccine is designed to target endogenous retroviral antigens (such as MelARV gp70) that are aberrantly expressed in various murine cancer models, including the 4T1 triple-negative breast cancer model. When administered mucosally (intranasally), Ad5-MuLV gp70, often co-delivered with an Interleukin-1β-encoding vector or other tumor-associated antigen vectors like Ad5-Mage-b, robustly induces tumor-specific tissue-resident memory T cells (TRM) in the lungs. This localized immune response has been shown to significantly prevent and treat pulmonary metastases and improve survival in preclinical breast cancer models.
- Other names
- Ad5-gp70Ad-5-gp70Ad 5-gp70Ad5-MuLV gp70 vaccineAd-5-MuLV gp70 vaccineAd 5-MuLV gp70 vaccineAd5-MuLV-gp70Ad-5-MuLV-gp70Ad 5-MuLV-gp70
02
Targets
CXADR (Coxsackievirus and adenovirus receptor)Integrin alpha-V-containing complexesMurine leukemia virus envelope glycoprotein gp70
Beyond the preview
Go deeper on Ad5-MuLV gp70.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad5-MuLV gp70.